Background: There are potential benefits to individualizing dosage in patients treated with efavirenz (EFV). We tested a simplified algorithm based on a Bayesian pharmacokinetic approach for guiding dose reduction in patients with EFV concentrations above the 75th percentile (P75) with documented virological efficacy. Methods: We designed a prospective, open-label, multicentre study. All consenting participants with EFV concentrations above P75 on standard dosage were included in a dose-reduction cycle. Primary end point was the number of patients who reached plasma concentrations within target (1,000-4,000 ng/ml) after, at most, two cycles of dose reduction at 3 and 6 months. CYP2B6 genetic characterization was performed. Results: Seventy-two patients were screened and 13 fulfilled selection criteria. These patients, with undetectable viraemia on a stable 600 mg EFV-based regimen, had a median (interquartile range) EFV plasma level of 8,112 ng/ml (5,993-10,278) at baseline; 38% (between P75 and P95) qualified for a 400 mg EFV dose, and 62% (above P95) qualified for a 200 mg EFV dose. After one to two dose-reduction cycles, all patients reached targets for EFV plasma concentration at 24 weeks. The predictive dose reduction based on genetic profile differed from dose reduction according to therapeutic drug monitoring (TDM) in three patients. All patients maintained viral suppression at 6 months. Conclusions: A standardized TDM-guided EFV dosereduction strategy over a 24-week period was successful, safe and yielded EFV plasma concentrations within the recommended therapeutic range. In addition to improving neuropsychiatric tolerability, EFV dose reduction has the potential to substantially decrease treatment cost.
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Therapeutic drug monitoring (TDM) of efavirenz (EFV) identifies high or low concentrations which might be responsible for increased toxicity or for decreased efficacy [1] . In April 2003, the first version of a guideline to optimize TDM in HIV clinical care was presented. An update has been published in 2006 and recommends using TDM in selected patients, such as those with impaired renal or hepatic function, pregnancy or suspected drug-drug interaction, for example [2] .
Investigations regarding the benefit of TDM in unselected populations have yielded conflicting results [3] [4] [5] [6] because of the lack of standardized criteria in measurement of antiretroviral plasma concentrations, or in defining thresholds for dose change. A recent Cochrane systematic review concluded that there is a lack of support for routine use of TDM, but also underscored the lack of data to identify selected populations that might benefit from its use [7] .
Prospective studies have demonstrated the relationship between EFV plasma concentration and clinical efficacy and toxicity, even in long-term users [1, [8] [9] [10] . Moreover, EFV is metabolized mainly by cytochrome P450 (CYP) 2B6, and its concentration is associated with CYP2B6 variation [11] . A recent study has tested the feasibility of a CYP2B6 genotype-based dose reduction of EFV, with less central nervous system [12] . More recently, the result of the ATHENA cohort demonstrated that TDM-guided EFV dose reduction in patients with high plasma concentrations did not compromise virological efficacy and led to a decreased risk of treatment discontinuation [13] . In addition to benefits in terms of tolerability, dose reduction can also influence individual treatment cost. Minimum effective dose can vary with interindividual differences in body weight, pharmacogenetic make-up and other factors [14] . Dose recommendations have often been derived from clinical trials that were not designed to establish minimum effective doses for individual patients. For example, EFV has been licensed by the US Food and Drug Administration in 1998 at a fixed 600 mg once-daily dose. A Phase II trial (DMP 005) showed no difference in efficacy between 200, 400 and 600 mg once-daily doses, when combined with zidovudine and lamivudine [15, 16] . We aimed to test a simplified algorithm for dose reduction in patients with documented virological efficacy, treated by a stable EFV 600 mg once daily based regimen while presenting with elevated plasma concentrations. We used a standardized algorithm, based on a Bayesian population pharmacokinetic model developed by our group [17] , to reduce doses in patients with plasma EFV concentrations above percentile 75 (P75). We hypothesized that dosage individualization was feasible and safe.
Methods

Patients
Patients were recruited at two University Hospitals (Service of Infectious Diseases, Lausanne University Hospital CHUV, Lausanne and HIV Unit, Geneva University Hospital, Geneva, Switzerland) from November 2006 to March 2008. All patients were on a stable EFV regimen (600 mg once daily), with a viral load <40 copies for ≥3 months. An EFV plasma concentration found above P75 at screening was confirmed on baseline, and the patients had to sign an informed consent form.
The protocol was approved by the Human Research Ethics Committees of Lausanne and Geneva University Hospitals. The study was conducted in accordance with the ethical principles laid out in the Declaration of Helsinki (1996) 
Study design
This study was a prospective open-label multicentre trial on patients screened with an EFV plasma concentration above P75, measured between 8 to 24 h postdose. Blood samples were taken at least 8 h after the last EFV dose intake, to ensure that sampling was taken during the elimination phase of the drug. All patients fitting the inclusion criteria underwent a dose reduction according to a standardized scheme based on a Bayesian approach (Figure 1 ). This approach evaluates the most likely contribution of intra-and interindividual variability in EFV kinetics, and adjusts the dosage specifically with respect to interindividual variability. Drug dosage was modified according to the protocol on week 2, after the confirmation that the EFV plasma concentration at baseline remained above P75. Patients with EFV concentration between P75 and P95 received EFV 400 mg once daily (two 200 mg tablets), whereas those with concentrations above P95 received EFV 200 mg once daily (one tablet). Plasma concentrations were then checked again on week 6. If EFV concentration was still above target, a second cycle of dose reduction was to be performed. EFV plasma concentrations were then monitored on weeks 10 and 24 for all patients. The protocol did not allow for more than two cycles of drug dosage adjustment. The primary end point was the number of patients who reached a plasma concentration within target (1,000-4,000 ng/ml) after at least one cycle (and maximum two cycles) of dose reduction at 6 months, according to the provided algorithm. The percentage of patients remaining with undetectable viral load at 3 and 6 months was also determined as a secondary end point.
Other laboratory measurements were also performed at baseline and at weeks 10 and 24: viral load, CD4 + T-cell count, serum alanine aminotransferase, total cholesterol, triglycerides, high-density lipoprotein, low-density lipoprotein, glucose, creatinine, full blood cell count measurements and a pregnancy test (if required).
All patients completed questionnaires at baseline, week 10 and week 24. All questionnaires were administered by a trained study nurse. Symptoms of depression, anxiety and stress were assessed with the Depression Anxiety and Stress Scale (DASS) [18] . This scale was chosen for its high internal consistency, temporal stability and stable factor structure [19] . The DASS scale distinguishes among normal, mild, moderate, severe and extremely severe degrees of depression, anxiety or stress. Sleep quality was measured using Groningen Sleep Quality Score (GSQS) [20] .
Finally, patients were genetically characterized for CYP 2B6, 2A6 and 3A4 [21] , in order to document the influence of polymorphisms on EFV concentrations and the prediction of dose reduction (see Genetic analyses section).
Plasma concentrations
EFV total plasma concentrations were determined by HPLC coupled to tandem mass spectrometry (LC-MS/MS) after protein precipitation with acetonitrile (MeCN) using an adaptation of our previously reported methods [22, 23] .
EFV pure substance, kindly provided by Merck Sharp & Dohme-Chibret AG (Glattbrugg, Switzerland), was used to prepare calibration and quality control samples. The internal standard used was EFV-d 4 , kindly provided by Toronto Research Chemicals Inc. (North York, ON, Canada).
We used selected transitions and collision energy previously reported [22] , with some minor modifications: the m/z transition, collision energy (V) and tube lens used were 314.0→244.0, 29 and 60 for EFV, and 318.0→248.0, 27 and 37 for EFV-d 4 . The range of calibration curves was established up to 10,000 ng/ ml, with a lower limit of quantification of 250 ng/ ml. The laboratory participates in an international external quality assurance program for the analysis of concentrations of antiretroviral drugs (Association for Quality Assessment in TDM and Clinical Toxicology [KKGT], The Hague, the Netherlands). In the last three external quality control rounds, the deviations from target quality control values were always within 1 to 6%.
Adherence
Adherence to EFV was assessed by using an electronic pill container, the Medication Event Monitoring System (MEMS ® ; AARDEX, Zug, Switzerland) [24] , which allowed us to assess longitudinally the patient's drugdosing history (that is, date and exact time of each opening of the pill container), and to compare it with the prescribed drug-dosing regimen and drug plasma level. Electronic data were combined with pill count and patients' interviews. EFV adherence was defined as the percentage of days with correct dosing according to physician's prescription.
Genetic analyses
CYP2B6 genetic characterization was carried out for all patients. When CYP2B6 function was impaired, additional characterization of the accessory pathways CYP2A6 and 3A4 was performed [11, [25] [26] [27] .
In order to comprehensively characterize CYP2B6 function in patients with plasma concentrations above P75, all nine CYP2B6 exons and intron-exon boundaries (4299 bp) were fully resequenced. Primers and conditions were previously published [11, 28] . On account of the working hypothesis that CYP2A6 and CYP3A4 The grey area represents efavirenz (EFV) plasma concentrations for which a dose reduction was performed. Circles and squares represent EFV plasma concentrations at baseline for patients included in the study (n=13). White circles represent patients above percentile 95 (P95), qualifying for a 200 mg dose; the white square represents the patient above P95 who needed two cycles of dose reduction; grey circles represent patients between percentile 75 (P75) and P95, qualifying for a 400 mg dose.
decrease or loss-of-function (LOF) alleles would be clinically relevant among patients with impaired CYP2B6 metabolism [21, 27] , CYP2A6 and CYP3A4 were characterized in patients homozygous for an LOF allele of CYP2B6. Given the large number of functional alleles associated with CYP2A6 LOF and their high prevalence, CYP2A6 characterization included full resequencing (promoter region, all nine exons and intron-exons boundaries [4357 bp]), gene conversion and gene copy number assessment, as described [21] . Given the paucity of functional alleles associated with CYP3A4 LOF, despite extensive investigation by many groups over the years [29] , only the two most frequent and potentially functional alleles/variants CYP3A4*1B [30, 31] and CYP3A4 rs4646437 [32] were genotyped by TaqMan allelic discrimination. Primers and probes were described elsewhere [33] or obtained by assay (TaqMan ® SNP Genotyping Assay: C_32306227 10) on demand at Applied Biosystems (Darmstadt, Germany), respectively, for CYP3A4*1B and CYP3A4 rs4646437 genotyping. Genotyping results did not interfere with the decision process of lowering the EFV dosage and were submitted to a post-hoc analysis; however, we hypothesized that all patients included in this study should be homozygous for an LOF allele of CYP2B6, as they were chosen to undergo EFV dose reduction according to TDM data. In order to compare the predictive effectiveness of the genotype in comparison to TDM, we built the following prediction model: patients with impaired CYP2B6 metabolism, but no LOF in the accessory pathways (CYP2A6 and CYP3A4), were expected to need a one unit EFV dose reduction (resulting in a 400 mg once-daily regimen). Patients with impaired CYP2B6 metabolism and carrying one or more LOF alleles in CYP2A6 and/or CYP3A4 were expected to need a two unit EFV dose reduction (resulting in a 200 mg once-daily regimen).
Statistical analyses
Differences in EFV plasma concentrations, in scores for DASS questionnaires, and in safety parameters between screening and/or baseline visits and week 24, were analysed with a non-parametric Wilcoxon matched-pairs test with a significance threshold of 5%. The quantitative score for GSQS questionnaire was collapsed into a binary variable: undisturbed to moderately disturbed sleep (score ≤5) versus very disturbed sleep (score >5), and analysed using a χ 2 test with a threshold of 5%. Statistical analyses were performed using STATA Release 10.0 (Stata Statistical Software; Stata Corporation, College Station, TX, USA).
Results
Patients
Out of 72 participants screened for the study, 15 (21%) were candidates for EFV dosage adjustment at baseline. Two subjects decided to stop the study at baseline and were excluded from the final analysis. One withdrew consent, the other had incident tuberculosis; thus, 13 patients were included in the study at baseline (Table 1) : 62% were male, median age was 45 years; seven were Caucasian from Western Europe, four were born in Africa and two were of Hispanic/Latin origin. All had undetectable viraemia and were exposed to EFV for 4.3 years (median) at baseline. Additionally, they were receiving either the combination of emtricitabine and tenofovir (n=5), abacavir and lamivudine (n=7), or tenofovir plus lamivudine (n=1). Six patients were also on non-HIV medications such as anti-inflammatory drugs (ibuprofen, n=2), lipid-lowering drugs (n=2), angiotensin-converting enzyme inhibitors (n=2) or neuropsychiatric drugs (escitalopram and benzodiazepine, n=1).
Dose adaptation
Screening and baseline samples were drawn between 9.25 h and 22.3 h after last dose intake. At baseline five patients (38%) had EFV concentrations between P75 and P95, qualifying for a 400 mg dose ( Figure 1) . As a result, the median (interquartile range [IQR]) EFV plasma concentration decreased from 5,206 (5,076-5,993) ng/ml at baseline to 3,021 (2,937-3,261) ng/ml at week 6 (P=0.043). Eight patients (62%) had concentrations above P95 and underwent a dose reduction directly from 600 mg once daily to 200 mg once daily (Figure 1 ). In this group, median (IQR) EFV concentrations decreased from 9,644 (8,335-10,348) ng/ml to 2,483 (2,111-2,861) ng/ml (P=0.012). For one patient, dose reduction was erroneously carried out at 400 mg once daily instead of 200 mg once daily on the first cycle, and required a second cycle of dose reduction to reach the recommended therapeutic interval. After dose reduction, EFV drug concentrations remained above the trough threshold of 1,000 ng/ ml, recommended by the US Food and Drug Administration, in all patients (Figure 2 ). Moreover, all EFV plasma concentrations (median, range) remained below 4,000 ng/ml on week 10 (2,826 ng/ml, 1,571-3760) and on week 24 (2,707 ng/ml, 1,604-3,940).
Interestingly, the reduction in concentration after dosage adjustment was greater than the dosage reduction itself, both in the patients who changed to 400 mg once daily (41% versus 33%) and in those who changed to 200 mg once daily (76% versus 67%); this was not an effect of sampling time differences.
Virological status
At the beginning of the study, all patients had a viral load <40 copies/ml by protocol. On weeks 12 and 24, all patients except one remained undetectable. One patient had an isolated blip on week 24 (54 copies/ml), but viral load was again below the detection level (<40 copies) on subsequent monitoring 12 months after study interruption without dosage change. This patient had been adjusted to an EFV dose of 400 mg once daily.
Safety
We observed a significant reduction in anxiety scores (P=0.036) and a trend in lower stress scores (P=0.077) in patients after dose reduction on week 24, as measured by the DASS questionnaire ( Table 2) . We also recorded a small but significant increase in CD4 + T-cell count between study start and termination. By contrast, no change in sleep quality or length was identified. During the study period, one serious adverse event was declared; the patient experienced acute renal insufficiency and rhabdomyolysis that was thought to be related to cocaine consumption and not to the study drug.
Adherence
Eleven patients, out of the thirteen included, used the electronic pill-container. One patient refused the electronic pill-container and another one often prepared EFV doses in advance, thus invalidating the adherence data, which were discarded from the analysis. The median (IQR) adherence to EFV was 99% (98-100) in the 11 included participants. Out of a total of 1,771 monitored days, there were only 31 (1.7%) days without any EFV drug intake, whereas 15 (0.8%) days were reported with more than one EFV intake.
Genetic analyses
Twelve patients were characterized for CYP2B6, 2A6 and 3A4. No genetic consent could be obtained for one patient. All patients were homozygous for a CYP2B6 LOF allele, except one patient who was heterozygous for an uncharacterized CYP2B6 allele. As we could not determine whether this allele led to an LOF, we included this patient for the further assessment of the accessory pathways CYP2A6 and CYP3A4. Three patients did not carry any CYP2A6 or CYP3A4 LOF, and were therefore expected to need a one unit EFV dose reduction (resulting in a 400 mg once-daily regimen). Nine patients had at least one CYP2A6 and/ or CYP3A4 LOF allele, and were therefore expected to need a two unit EFV dose reduction (resulting in a 200 mg once-daily regimen). The results are shown in Table 3 . When comparing the predictive EFV dose reduction according to either TDM or genotype, all but three patients were classified in the same category and would have received a similar EFV dosage. Figure 2. EFV concentrations before and after dose reduction in patients during the study Data is from 13 patients. The area within the horizontal lines represents the target efavirenz (EFV) concentration (1,000-4,000 ng/ml) [8] . White circles represent patients qualifying for a 200 mg dose; the white square with dotted line represents the patient who needed two cycles of dose reduction; grey circles represent patients qualifying for a 400 mg dose.
Discussion
Our study indicates that TDM-guided EFV dose reduction is successful and safe, without any negative effect on virological outcome at follow-up. The use of a standardized Bayesian algorithm enabled correct dose reduction to target therapeutic range (1,000-4,000 ng/ ml), without reaching subtherapeutic concentrations. Adherence to EFV was monitored electronically in order to ensure high level drug intake.
There are several reports suggesting that EFV could be used at reduced dose. Firstly, dose recommendations have often been derived from clinical trials that were not designed to establish minimum effective doses in individual patients. Phase II dose-ranging studies did not show differences in virological efficacy among 137 treatment-naive patients randomized to 24 weeks of treatment with zidovudine and lamivudine plus EFV at doses of 200 mg, 400 mg or 600 mg once daily, or matching placebo. There was no difference in HIV RNA suppression rates between the three doses of EFV and these efficacy results were sustained to week 24 [15, 16] . Secondly, a study of 180 individuals reduced 49 patients with high plasma drug concentrations from 600 mg to 400 mg without reporting virological risks with this strategy [13] . Our study shows that with a clear algorithm built up on population pharmacokinetic data to derive a simple percentile-based strategy, drug reduction is feasible without jeopardizing efficacy.
Reducing drug exposure has been associated with a decrease in adverse events and toxicity symptoms, although neuropsychological toxicity may persist longer because of long-term therapy [8, [34] [35] [36] [37] . In patients initiating an EFV-based regimen (n=108), stepped-dose versus full dose EFV proved to be of similar efficiency in a randomised trial [38] . In the present study, patients were not selected for adverse events; we observed, nonetheless, a significant reduction in anxiety scores and a trend in lower stress scores in patients on reduced dosing. No change in sleep quality or length, as measured by a standardized questionnaire, was identified; however, on study completion, all patients without exception chose to remain on the reduced dose, despite the intake of one additional pill for those receiving 400 mg once daily (that is, two 200 mg pills), compared to the standard treatment (that is, one 600 mg pill).
When considering the lifelong treatment, the reduction in drug exposure might translate into a decreased number of side effects.
The effect on overall drug costs can also be relevant; 600 mg pills cost 499 USD/month in Switzerland, whereas the cost of the 400 mg daily dose is 299 USD/month, and the cost of 200 mg once daily is 166 USD/month. We have assumed two TDM assessments (278 USD) and a comprehensive genetic analysis (200 USD). The economic analysis reveals a cost saving of the 400 mg dose reduction of 1,857 USD per year per patient, and of 3,453 USD per year per patient for a 200 mg dose reduction. The Swiss HIV Cohort Study (SHCS) comprises more than 80% of all HIV-infected patients followed-up in Switzerland: if 15% of the patients on EFV-based regimen had a dose reduction to 400 mg, and 10% to 200 mg according to TDM, the overall saving could be as high as 1,178,101 USD per year. EFV is not the only drug where cost could be decreased by lowering drug dosage; studies are ongoing with lamivudine, lopinavir/r and zidovudine, for example [39] .
Drug dosage reduction could have been predicted with nearly similar precision using genetic testing, instead of TDM, although the post-hoc nature of the CYP2B6 genetic characterization and the fact that no full genetic characterization was provided for EFV-tolerant patients not included in the study are potential limitations. The relative benefit of using one or the other strategy is unclear, considering that predictive dose reduction based on patient genetic profile differed from dose reduction according TDM in our study for three patients only. One patient underwent an EFV dose reduction to 200 mg/ day lower than predicted by the genotyping results (400 mg/day), and reached the lowest EFV concentration on week 24 in the study. Two patients underwent an EFV dose reduction to 400 mg/day despite genotyping prediction (to 200 mg/day), and reached the highest EFV plasma levels on week 24. Thus, it is conceivable that all three patients would have reached the recommended target therapeutic range through genotyping. Still, further studies are needed to confirm the predictive potential of genetic testing, and, more specifically, to compare strategies to better identify the patients most likely to benefit from drug dose reduction.
We recognize some limitations to our study; firstly the limited sample size does not allow generalization of our findings to different population groups. Secondly, there was no randomization, and all patients benefited from a drug dose reduction. Thirdly, per protocol, patients had a maximum of two cycles of dose reduction to reach plasma concentrations within target (1,000-4,000 ng/ ml). In our experience, all patients but one fell into the drug plasma concentration target after the first cycle of dose reduction. For patients who reached the upper part of the therapeutic target range (that is, 3,000-4,000 ng/ml), there is no evidence of a clinical benefit to be expected from a second dose reduction.
The observation of larger than proportional reductions in concentration after dose reduction might indicate some non-linearity in EFV clearance, as well as non-specific regression to the mean, justifying our Bayesian approach to EFV TDM, and further non-captured influences (for example diet or interacting comedications).
In conclusion, TDM-guided dose reduction in this and in other studies [12, 13] appears safe and should be considered in patients with high EFV concentrations; EFV dose reduction also prevents toxicities and minimizes treatment cost. This is also of particular interest for resource limited settings as WHO recently issued revised recommendations suggesting that EFV be the preferred regimen. University, Liverpool, UK and Dr Alain Nguyen, Geneva University Hospital, Geneva, Switzerland.
The study was funded, in part, by educational grants from Geneva University Hospital. The SHCS is financed in the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation.
The Swiss National Science Foundation (Grant numbers 324700-112655 and 32430-124943) has supported, in part, the salary of AFM and JdI. LAD has received a REQUIP Grant number 326000-121314/1 from the Swiss National Science Foundation for the acquisition of new LC-MS/MS instrumentation.
These 
Disclosure statement
The authors declare no competing interests.
